The low molecular weight heparin market in Europe is expected to grow from US$ 1,315.04 million in 2021 to US$ 2,021.53 million by 2028; it is estimated to grow at a CAGR of 6.3% from 2021 to 2028.
Low molecular weight heparins (LMWH) can be subcutaneously administered once a day without the need for any supervision. However, the effects of unfractionated heparin (UFH) or standard heparin vary from patient to patient. Therefore, it can only be administered to hospitalized patients under supervision. In addition, the LMWH has more predictable pharmacokinetic properties compared to unfractionated heparin, which allows its administration in fixed doses based on laboratory monitoring, without the need for dose adjustments. The low molecular weight fractions of heparin have the molecular weight of ~3,500–8,000 Daltons, while unfractionated heparin has a molecular weight of 15,000 Daltons; thus, the former react less with platelets than the latter. Moreover, the LMWH is less likely to induce immune allergic thrombocytopenia, which is a severe side effect of unfractionated heparin (UFH). This condition is often complicated by arterial thrombosis. In addition, properties such as better bioavailability, predictable dose-response, and longer plasma half-life than unfractionated heparin make low molecular weight heparin a preferred choice for anticoagulation therapy. Such advantages of the LMWH over unfractionated heparin are boosting its demand, thereby spurring market growth, which is further anticipated to drive the market in Europe.
The COVID-19 outbreak curve continues to fluctuate, moving from bad to worse in Europe. This is irrespective of the fact that the European countries vary significantly in size, population, natural resources, economy, and political stability. Governments of European countries imposed various restrictions to control the effects of the outbreak in 2020 and early 2021. This led to disruptions, limitations, challenges, and changes in each sector of every industry. The COVID-19 pandemic also impacted the performance of the low molecular weight heparin (LMWH) industry. After the onset of the COVID-19 pandemic, the adoption of strict social containment measures and reorganization of healthcare systems helped them cope with the enormous increase in the number of patients.
Europe Low Molecular Weight Heparin Market Revenue and Forecast to 2028 (US$ Million)
Europe Low Molecular Weight Heparin Market Segmentation
Europe Low Molecular Weight Heparin Market – By Product Type
- Enoxaparin
- Dalteparin
- Tinzaparin
- Fraxiparine
- Nadroparin
- Others
Europe Low Molecular Weight Heparin Market – By Packaging
- Multi-Vials
- Prefilled Syringes
Europe Low Molecular Weight Heparin Market – By Application
- Deep Vein Thrombosis
- Acute Coronary Syndrome (ACS)
- Pulmonary Embolism
- Others
Europe Low Molecular Weight Heparin Market – By End User
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Others
Europe Low Molecular Weight Heparin Market– By Country
- U.K.
- Germany
- France
- Italy
- Spain
- Rest of Europe
Europe Low Molecular Weight Heparin Market-Companies Mentioned
- Abbott
- Aspen Holdings
- B. Braun Medical Inc.
- Dr. Reddy's Laboratories
- LEO Pharma A/S
- Novartis
- Pfizer Inc.
- Sanofi
- TEVA PHARMACEUTICAL INDUSTRIES LTD
Europe Low Molecular Weight Heparin Market Strategic Insights
Europe Low Molecular Weight Heparin Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 1,315.04 Million |
| Market Size by 2028 | US$ 2,021.53 Million |
| CAGR (2021 - 2028) | 6.3% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product Type
|
|
Regions and Countries Covered
|
|
| Europe | UK, Germany, France, Russia, Italy, Rest of Europe |
| Market leaders and key company profiles |
|
Europe Low Molecular Weight Heparin Market Country and Regional Insights
